Sigilon Therapeutics, Inc. SGTX
22.47 +22.47
Day range unavailable
52-week range unavailable
Analyst view
Consensus: buy
Buy
Price target (mean) 47.33 +110.6% upside
Now 22.47
- Target (low)
- 21.00
- Target (mean)
- 47.33
- Target (high)
- 91.00
Ratings (-1m) 4 3 buy · 1 hold · 0 sell
- Strong buy2
- Buy1
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- 1 month ago 4
- 2 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -4.71 | -6.46 – -2.97 | -5.72 | +17.7% | 4.25M | +47.4% | 2 |
| Next quarter | -3.28 | -3.58 – -2.99 | -3.51 | +6.6% | 4.25M | 0.0% | 2 |
| Current year | -9.37 | -12.65 – -3.55 | -17.42 | +46.2% | 15.77M | +21.8% | 3 |
| Next year | -12.86 | -14.87 – -10.71 | -9.37 | -37.2% | 16.00M | +1.5% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 18, 2023 | Canaccord Genuity | Initiated | — | Buy |
| Dec 23, 2021 | Canaccord Genuity | Maintained | — | Buy |
| Dec 1, 2021 | Barclays | Maintained | — | Overweight |
| Nov 30, 2021 | Morgan Stanley | Maintained | — | Equal-Weight |
| Nov 30, 2021 | Jefferies | Downgrade | Buy | Hold |
| Oct 29, 2021 | BTIG | Initiated | — | Buy |
| Jul 19, 2021 | Canaccord Genuity | Maintained | — | Buy |
| Jul 16, 2021 | Morgan Stanley | Maintained | — | Equal-Weight |
| Jan 8, 2021 | Canaccord Genuity | Initiated | — | Buy |
| Dec 29, 2020 | Morgan Stanley | Initiated | — | Equal-Weight |
| Dec 29, 2020 | Jefferies | Initiated | — | Buy |